Cancer Family
Pancreaticobiliary Neoplasm
CI-CAN-00000309Explore in graph →
Non-malignant1,205 active trials11 approved drugs92 evidence items
- NCIt
- C223357
Loading cancer entity…
Cancer Family
CI-CAN-00000309Explore in graph →
Clinical trials
5,005 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06587061 | HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer | recruiting | Phase 2 | 30 | Ruijin HospitalOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT07131514 | HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer | recruiting | Phase 2 | 30 | Ruijin HospitalOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT07608627 | 64Cu-DOTA A2 scFv-Fc2 DM With Positron Emission Tomography for the Imaging of Patients With Locally Advanced or Metastatic PSCA-Expressing Pancreatic Cancer | not yet recruiting | Phase 1 | 15 | City of Hope Medical CenterOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT04504604 | TCF-001 TRACK (Target Rare Cancer Knowledge) Study(TRACK) | recruiting | N/A | 400 | TargetCancer FoundationOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT05546372 | Endobiliary Radiofrequency Ablation for Malignant Biliary Obstruction Due to Perihilar Cholangiocarcinoma(RACCOON) | recruiting | N/A | 122 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT06090916 | Malnutrition Screening and Dietary Intervention to Improve Nutrition Outcomes in Patients With Unresectable Pancreatic Cancer | active not recruiting | N/A | 100 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT06274879 | Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer(Ablatio) | recruiting | Phase 2 | 36 | Insel Gruppe AG, University Hospital BernOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT06427239 | Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal Adenocarcinoma | recruiting | Phase 1 / Phase 2 | 130 | Fudan UniversityOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT06937567 | CDH17 CAR-T Therapy in Advanced Malignant Solid Tumors | recruiting | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07557849 | Multicentric Database for KRAS Mutant Pancreatic Cancer | recruiting | — | 1,000 | Fudan UniversityOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07605702 | The Canopy Cancer Collective Clinical Registry Protocol | not yet recruiting | — | 100,000 | Canopy Cancer Collective, LLCNETWORK | 1 | May 26, 2026 | clinicaltrials |
| NCT07606430 | Comparison of a Short Modified Metal Stent Versus Plastic Stent as a Bridge to Surgery in Pancreatic Cancer With Malignant Biliary Obstruction(BRIDGE-8) | not yet recruiting | N/A | 116 | Soonchunhyang University HospitalOTHER | 0 | May 26, 2026 | clinicaltrials |
| NCT07607912 | Clinical, Oncological and Metabolic Effects of Pancreatic Mass Loss After Partial, Near-total and Total Pancreatectomy in Patients With Preoperative Diabetes Mellitus(DCP-DM) | not yet recruiting | — | 408 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 0 | May 26, 2026 | clinicaltrials |
| NCT04452357 | Pulse-low-dose Rate (PLDR) Radiation in Pancreatic Cancer | active not recruiting | N/A | 12 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04484909 | NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer | active not recruiting | Phase 1 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05053555 | High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies | recruiting | N/A | 60 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05225428 | Video Education With Result Dependent dIsclosure(VERDI) | recruiting | N/A | 1,020 | Dana-Farber Cancer InstituteOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05365893 | PHL Treatment in Pancreatic Cancer | active not recruiting | Early Phase 1 | 20 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06238479 | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors(EXCEED) | active not recruiting | Phase 1 | 490 | Eli Lilly and CompanyINDUSTRY | 7 | May 22, 2026 | clinicaltrials |
| NCT06868849 | A Study of JMT203 in Patients With Cancer Cachexia | recruiting | Phase 1 / Phase 2 | 307 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT06998940 | Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations | recruiting | Phase 3 | 94 | SWOG Cancer Research NetworkNETWORK | 1 | May 22, 2026 | clinicaltrials |
| NCT07595835 | CT-guided Percutaneous Radionuclide Therapy With 32P Microparticles in Patients With Non-progressive Locally Advanced Pancreatic Cancer(PANCOSIL) | recruiting | Phase 1 / Phase 2 | 20 | M.R. MeijerinkOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03187951 | PancFit: Multimodal Exercise During Preoperative Therapy for Pancreatic Cancer | active not recruiting | N/A | 152 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT06885424 | A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products(DESCENT-1) | enrolling by invitation | — | 400 | A2 Biotherapeutics Inc.INDUSTRY | 1 | May 20, 2026 | clinicaltrials |
| NCT07481357 | A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma | recruiting | Phase 1 | 51 | Dong-A ST Co., Ltd.INDUSTRY | 1 | May 20, 2026 | clinicaltrials |
| NCT07598318 | Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations | not yet recruiting | Phase 2 / Phase 3 | 164 | Sir Run Run Shaw HospitalOTHER | 0 | May 20, 2026 | clinicaltrials |
| NCT07600268 | Efficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Maintenance Therapy Compared to Maintenance Therapy Alone in Advanced Pancreatic Cancer | recruiting | Phase 2 | 24 | Shandong Cancer Hospital and InstituteOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT05184790 | LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology(LEARN) | recruiting | — | 300 | University of SydneyOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT05431270 | Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) | recruiting | Phase 1 / Phase 2 | 40 | Phanes TherapeuticsINDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT06503146 | 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection | recruiting | Phase 2 | 320 | National Cancer Institute (NCI)NIH | 1 | May 19, 2026 | clinicaltrials |
| NCT06904378 | ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma | recruiting | Phase 1 / Phase 2 | 61 | Washington University School of MedicineOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07173387 | Stereotactic Body Radiotherapy and NALIRIFOX for Locally Advanced Pancreatic Cancer(RAD-NALIRIFOX) | active not recruiting | Phase 2 | 42 | Shandong Cancer Hospital and InstituteOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07280377 | A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab(GOBLET) | active not recruiting | Phase 1 / Phase 2 | 122 | Oncolytics BiotechINDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT07594964 | To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors | recruiting | Phase 1 | 48 | Shenzhen Xinhe BiomedicalINDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT07595172 | NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 55 | West China HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07596732 | Statewide Unified Network for Remote Intervention of Strength and Exercise(SUNRISE) | not yet recruiting | N/A | 120 | AdventHealth Translational Research InstituteOTHER | 0 | May 19, 2026 | clinicaltrials |
| NCT07597772 | Preliminary Trial of SNA014 for Pancreatic Cancer | recruiting | Early Phase 1 | 12 | SmartNuclide BiopharmaINDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT04421820 | BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 220 | Bold Therapeutics, Inc.INDUSTRY | 7 | May 18, 2026 | clinicaltrials |
| NCT05727020 | Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma(VAPOR) | recruiting | — | 1,005 | Imperial College LondonOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT07014878 | A Study of DCTY1102 Injection in Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 18 | Beijing DCTY Biotech Co.,Ltd.OTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT07094204 | A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors | recruiting | Phase 1 | 364 | Astellas Pharma IncINDUSTRY | 4 | May 18, 2026 | clinicaltrials |
| NCT07592819 | A Trial Using Transcriptomic Signatures to Personalize Neoadjuvant Chemotherapy (NAC) for Patients With Resectable Borderline Pancreatic Adenocarcinoma (PDAC)(PRODIGE 104 B) | not yet recruiting | N/A | 367 | Institut Paoli-CalmettesOTHER | 0 | May 18, 2026 | clinicaltrials |
| NCT04042831 | Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations | active not recruiting | Phase 2 | 32 | Academic and Community Cancer Research UnitedOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT04137536 | A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer | active not recruiting | Phase 1 | 7 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT04927780 | Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer(PREOPANC-3) | active not recruiting | Phase 3 | 378 | Erasmus Medical CenterOTHER | 2 | May 15, 2026 | clinicaltrials |
| NCT05379985 | Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | recruiting | Phase 1 / Phase 2 | 754 | Revolution Medicines, Inc.INDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT05462717 | Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | active not recruiting | Phase 1 | 222 | Revolution Medicines, Inc.INDUSTRY | 13 | May 15, 2026 | clinicaltrials |
| NCT07138846 | A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer | not yet recruiting | Phase 3 | 231 | Lepu Biopharma Co., Ltd.INDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT07591480 | Barriers And Facilitators To Clinical Trial Enrollment: A Qualitative Study Of Pancreatic Cancer Patients | not yet recruiting | — | 20 | M.D. Anderson Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07591493 | Adjuvant Trial in Pancreatic Neuroendocrine Tumors(ADJUPANET) | not yet recruiting | Phase 3 | 300 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | May 15, 2026 | clinicaltrials |
Data updated 24 days agoSource updated May 27, 2026source: clinicaltrials